



BREAKING NEWS:

MagVenture opens in Brazil

For people in Brazil with treatment-resistant depression, remission could now be a step closer: The Danish company MagVenture, who specializes in medical equipment for a groundbreaking non-drug treatment called TMS has, as of November 1st 2019, opened a new subsidiary in Sao Paulo, Brazil.

Transcranial Magnetic Stimulation, or TMS in short, is a non-invasive technology which delivers magnetic pulses to stimulate nerve cells in the part of the brain controlling mood, an area often underactive in depressed patients. The treatment has no systemic side effects, and does not require anesthesia. TMS is currently undergoing a rapid growth worldwide, not just within depression treatment but also in brain research as well as neuro-diagnostics.

“Over the past 5 years, we’ve seen a tremendous growth within TMS research in Brazil, ranging from basic neuroscience, to physical therapy, pain management, and functional rehabilitation. Last but not least, several psychiatry practices now offer TMS and are seeing good results with their treatment-resistant depression patients,” says National Sales Manager for Brazil, Lucas Godoy. Globally, TMS for depression is particularly booming, and Lucas Godoy is certain that the same will happen in Brazil.

“Brazil has served as a beacon for Latin America, with several renowned researchers paving the way for a broader dissemination of TMS, both clinically and scientifically. The University of Sao Paulo has for years hosted well-attended TMS certification courses, attracting hundreds of healthcare professionals from across the country,” says Lucas Godoy, adding that other universities now have their own TMS research departments. “The next logical step for us is to further advance this positive development by establishing a MagVenture subsidiary here where we already have a large customer base.”

Denmark-based MagVenture built its very first stimulator over 25 years ago and has subsidiaries in the US, the UK, and Germany. “From our vast experience we know that physical presence and a strong local knowledge are vital in order to serve our customers best,” says Leonardo M. Gallardo, Area Sales Manager, MagVenture. “We believe that a subsidiary in Brazil will not only benefit our customers and the patients, but also let us build an even stronger position and presence in Latin America.”

Further information:

Lucas Godoy, National Sales Manager, MagVenture Ltda., Brazil: +55 11 97375-4488, lg@magventure.com

Major Depressive Disorder (MDD) is a leading cause of disability worldwide and although several treatment options are currently available, not all patients benefit from them; In fact, approximately 60% do not respond adequately to conventional treatments such as antidepressants and are therefore in dire need of an alternative. TMS is known to produce an antidepressant effect in approximately 50% of these hard-to-treat patients. MagVenture TMS Therapy® for the treatment of major depressive disorder was CE approved in Europe in 2011 and received FDA clearance in the US in 2015.

MagVenture A/S is a medical device company with over 25 years of experience within neuromodulation. From its headquarters in Denmark, MagPro magnetic stimulators are promoted worldwide through direct sales subsidiaries in Brazil, the US, Germany, the UK, and through an extensive global network of dedicated distributors in Europe, Asia, Middle East, and the Americas.